- Benchmark ASINB0GNTW9PPM
- MarketplaceUS
- Category ID7792528011
- Analyzed Products
- Keywordskin care
- Price Range-
- Minimum Net Profit Margin10.00%
- MOQ100
- Est. Purchasing CostNo price data
- Data Date2026-07-30
- Your Budget (for new listing) (CNY)¥500,000.00
Report summary from Keble AI Agent: Listing
结论很明确：这个市场不适合进入，当前已经处在高强度竞争和明显新品失败阶段。 新品整体盈利率只有25%，而且近几个月的新品里72.73%不赚钱；看起来整体盈利率60%并不差，但真正决定新人能不能活下来的，是新品这一层，而这里明显偏弱，且成功样本几乎都被少数强势品牌拿走。
Recommended Products Features Direction
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
New Brands
VS
Old Brands
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
New Brands
Old Brands
#Budget Requirement
Listing结论很明确：这个市场现在不适合进入。 你预算 50万CNY 只能覆盖少数单品的前期铺货和投放，但市场里新品盈利率只有25%，整体盈利率也只有60%，而且已经出现明显的品牌高投入、价格分层和新品失败信号；这不是一个值得小品牌硬冲的市场，也不值得大品牌在没有强创新和强预算的情况下进入。
Early sourcing + logistics + marketing budget (USD)$923,214.60 - $1,398,867.42Explains the budgetWith all these investments, who has profitable new releases
How many new listings are released by old brands?58.33%New listing success rate (old brands):28.57%New listing success rate (new brands):20.00%Which new brands have these successful new listings?Which old brands have these successful new listings?Other major expensesR&DAlternatives- 温和视黄醇/视黄醛入门精华：例如1%以内视黄醇、包裹型视黄醇或低浓度晚霜。相比0.1% retinal更便宜、刺激更低、上手更容易，适合先验证耐受度的人群。
- 壬二酸精华/乳霜：用于粗糙、痘印、泛红和毛孔观感管理，通常比高阶视黄醛更容易买到、白天也更灵活使用，风险更低。
- 烟酰胺+锌类收敛精华：价格通常更亲民，日常更好坚持，适合把“毛孔、出油、肤质不匀”作为主要诉求但不想上强刺激抗老的人。
- AHA/BHA温和去角质产品：如2%水杨酸或低浓度果酸棉片/精华，针对角质堆积、闭口和皮肤粗糙更直接，使用门槛比视黄醛低，且单次购买成本更可控。
- 多肽修护/紧致精华：如果用户核心诉求是细纹和紧致，但担心视黄醛刺激，可选择基础多肽产品；通常更好搭配现有护肤流程，也更适合敏感肌。
- 维C类提亮精华：适合把‘肤色暗沉、细纹、皮肤状态’作为主要目标的用户，很多基础款更容易在Amazon找到，且通常不需要像高强度视黄醛那样严格建立耐受。
- 含神经酰胺的修护面霜：当用户其实更需要‘屏障稳定、干燥、紧绷、泛红’改善时，先用修护霜往往比直接上高强度抗老更划算、更稳妥。
Alternative solutions may pose a risk to your investment in certain markets.
#Brands Investment Analysis
Listing结论很明确：这个市场不适合进入，已经出现明显过热和价格战信号。当前样本里新品牌只有1/4新发布产品盈利，成功率25%，看似不差，但失败样本集中在同一赛道、同质化严重，而且近几个月新发布里非盈利产品明显更多，说明后进者很容易被压住。
New products with Highest revenueLeast investment in new productsMost investment in new productsIOPE
Recent Monthly Revenue (USD):$14,565.00(300pcs/month)B0GNTW9PPM (4.5/5 (392 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableOld brand with the most profitable new productscelimax
Recent Monthly Revenue (USD):$1,883,000.00(100000pcs/month)B0DK4Y2YP3 (4.4/5 (20320 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitableRecent Monthly Revenue (USD):$428,400.00(10000pcs/month)B0GZ19T1SM (4.4/5 (20323 Reviews))Brand is an old entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableRecent Monthly Revenue (USD):$189,900.00(5000pcs/month)B0FQV2J48Q (4.6/5 (806 Reviews))Brand is an old entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableLeast profitable new productsSUNGBOON EDITOR
Recent Monthly Revenue (USD):-(-)B0H6ZC893HBrand is a new entry in this marketNew ReleaseInsufficient Sales to Meet MOQUnderperformingNot enough sales volume to meet 100 MOQ#Differentiations
Unique productsCommon productsDifferentiation:- 银白极简包装，和常见精华瓶差异很大
- |
- 微针刺点型定位，视觉上更有新奇感
- |
- 更适合追求进阶护理、想尝试居家微针感的人群
B0C2TSK62Y (4.5/5 (12598 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitableSales & BSR
Differentiation:- 双支礼盒装，和单支装、大容量装差异明显
- |
- 礼赠感更强，容易吸引点击
- |
- 更适合送礼或想先体验小规格的人群
B0FQV2J48Q (4.6/5 (806 Reviews))Brand is an old entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableSales & BSR
#Net Profit Margins: All vs New
Listing这不是适合进入的市场，已经进入高风险的价格战区，且明显偏向大品牌和高投入玩家；小商家不建议进入。 现有数据里，能赚钱的新品几乎都不是“轻量新卖家”能复制的路径：要么靠老牌实力，要么靠高投入、高定价和强品牌心智。
Profitability difficultyPotential high net profit marginAll products distribution on different profit levels
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%otherNew products distribution on different profit levels
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%other#Top Products by Net Profit Margin
Top 20 Profitable Products
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
B0DK4Y2YP3celimax2024-10-16Yes$18.83100000pcs$1883000.032.99%$621201.71B00PBX3L7KCOSRX2014-10-30Yes$18.0990000pcs$1628100.030.06%$489406.86B0DG1DQ2S7ANUA2024-09-04Yes$21.1670000pcs$1481200.028.74%$425696.88B0GZ19T1SMcelimax2026-05-08Yes$42.8410000pcs$428400.043.52%$186439.68B07VWSN95SCeraVe2019-08-14Yes$18.4930000pcs$554700.033.05%$183328.35B0FQV2J48Qcelimax2025-09-12Yes$37.985000pcs$189900.041.13%$78105.87B0C2TQ24VYVT COSMETICS2023-06-17Yes$23.378000pcs$186960.034.17%$63884.24
B0DCJ7952Pmedicube2024-08-08Yes$18.7610000pcs$187600.028.98%$54366.48B0C1Y8652XCOSRX2023-04-10Yes$35.03000pcs$105000.040.95%$42997.5B07XJ7XWLWCeraVe2019-09-09Yes$20.433000pcs$61290.035.06%$21488.28B0DQCLFJCBmedicube2024-12-13Yes$21.173000pcs$63510.033.51%$21282.21B0D16L5F2Mmedicube2024-04-08Yes$18.464500pcs$83070.024.66%$20485.07B0C2TSK62YVT COSMETICS2023-06-20Yes$31.071000pcs$31070.040.04%$12440.43B0GNTW9PPMIOPE2026-02-28Yes$48.55300pcs$14565.043.86%$6388.21
B0DQW3P7VXmedicube2024-12-19Yes$22.031000pcs$22030.025.33%$5580.2Top 20 Profitable New Products
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
B0GZ19T1SMcelimax2026-05-08Yes$42.8410000pcs$428400.043.52%$186439.68B0FQV2J48Qcelimax2025-09-12Yes$37.985000pcs$189900.041.13%$78105.87B0GNTW9PPMIOPE2026-02-28Yes$48.55300pcs$14565.043.86%$6388.21#New Product Success Rates
Listing这个市场不适合进入，尤其不适合小品牌；它不是“还能试试”的市场，而是已经被老牌和大牌卡住、且新产品大面积失败的高压市场。 新品里只有25.00%能达到可接受盈利，75.00%不赚钱；更关键的是，连续出现的高成功品牌几乎都来自老牌体系，说明真正的新品机会被少数强势品牌拿走了。
New products success rate.
What is the ratio of profitable products
Profitable (Unidentifiable released date)Profitable (Old product)Profitable (New product)Profitable (New product on old listing)New products but non profitableProfitable new products divide by brands
What is the ratio of different brands owning all profitable new products
celimaxIOPENonprofitable new products divide by brands
What is the ratio of different brands owning all nonprofitable new products
celimaxCOSRXmedicubeIOPESUNGBOON EDITORARENCIA#Success Rate by Entry Time
Listing这个市场不适合现在进入：新品牌成功率只有25%，而新品牌新品里75%都失败；更关键的是，最近新增品牌并不多，但失败集中、利润又被少数大品牌和老品牌拿走，说明门槛高、竞争硬。 你如果硬进，只能押注少数高预算、强品牌背书、且带明显创新的打法；对小 бизнес 来说，这不是可复制的顺风市场，而是明显偏向大品牌和重营销的战场。
2025到2026年，市场新增新品数量很少，但“能跑出来”的样本几乎只有 IOPE 的 B0GNTW9PPM 和 celimax 的 B0GZ19T1SM / B0FQV2J48Q。其中 IOPE 的 B0GNTW9PPM 目前是唯一的强样本：售价 $48.55，毛利率 43.9%，月销 300，最近月利润 $6,388.21，早期投入 $41,757.86；但同品牌另一款 B0GTX4MGJX 直接失败。celimax 也一样，B0GZ19T1SM 和 B0FQV2J48Q 虽然都能赚钱，毛利率分别 43.52% / 41.13%，但它们背后对应的总投入分别达到 923,214.6 和 1,398,867.42 美元级别，明显不是普通单品预算能轻松复制的打法。反过来，SUNGBOON EDITOR 的 B0H6ZC893H、ARENCIA 的 B0GKJHFD74、medicube 的 B0GWMM2QRN / B0GVY4RDDS、COSRX 的 B0H3NN446B 都是新近失败样本，说明最近进入者并没有形成稳定的成功面。**
对大品牌来说，能进，但必须按“高投入 + 强品牌 + 明显产品差异化”去打；对小 бизнес 来说，只有非常少的真成功案例，而且都不是低预算玩法。IOPE 是最该跟的样本，跟它的 B0GNTW9PPM；celimax 里可参考 B0GZ19T1SM 和 B0FQV2J48Q，但它们本质上都是高投入换结果，不是便宜试错。结论很直接：不要进入；如果非进不可，只适合大品牌复制 IOPE/celimax 这种高预算打法，小品牌没有足够安全边际。
How many products released each year
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
How many products released each month
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
#Net Profit Margins by Entry Time
Different profit ratios of products released in year
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2022 0 0 0 0 0 0 0 0 2023 0 0 0 0 0 0 0 0 2024 0 0 0 0 0 0 0 0 2025 0 0 0 0 0 0 1 2 2026 0 0 0 0 0 0 2 7 ≥ 10% Profitable< 10% UnprofitableUnidentifiableDifferent profit ratios of products released in month
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2025/7 0 0 0 0 0 0 0 0 2025/8 0 0 0 0 0 0 0 0 2025/9 0 0 0 0 0 0 1 2 2025/10 0 0 0 0 0 0 0 0 2025/11 0 0 0 0 0 0 0 0 2025/12 0 0 0 0 0 0 0 0 2026/1 0 0 0 0 0 0 0 1 2026/2 0 0 0 0 0 0 1 0 2026/3 0 0 0 0 0 0 0 1 2026/4 0 0 0 0 0 0 0 2 2026/5 0 0 0 0 0 0 1 0 2026/6 0 0 0 0 0 0 0 2 ≥ 10% Profitable< 10% UnprofitableUnidentifiable#Case Study
Success CasesCeraVe Resurfacing Retinol Face Serum with Niacinamide, Pore Minimizer, 1oz
This listing is deemed profitablePrice (USD)$18.49Released TypeOld Release (2019-08-14)Brand is an old entry in this marketSize and Weight12.6 x 5.6 x 3.6 cm, 30.00gProfitable Factors
Established brand with longevityBased on old ASINLow pricing strategyKey Buying Motive
含封装视黄醇、烟酰胺、甘草根提取物和神经酰胺，主打淡化痘印、平滑肤质并修护屏障Target Customers
有痘印、肤质粗糙、同时希望温和修护屏障的敏感/痘肌用户Early Investment
Investment
Monthly Revenue (Recent) (USD)$554,700.0030000 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight31.52% / 33.05%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight30.40% / 31.93%Peak / Non PeakSales & BSR Performance
CeraVe Retinol Serum for Face with Niacinamide & Hyaluronic Acid, 1 oz
This listing is deemed profitablePrice (USD)$20.43Released TypeOld Release (2019-09-09)Brand is an old entry in this marketSize and Weight12.0 x 3.7 x 3.5 cm, 30.00gProfitable Factors
Established brand with longevityBased on old ASINDistinct functions and featuresKey Buying Motive
封装视黄醇 + MVE缓释，主打温和持续释放，降低刺激感。Target Customers
适合敏感肌、干皮、首次尝试视黄醇且更看重温和修护的人群。Early Investment
Investment
Monthly Revenue (Recent) (USD)$61,290.003000 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight33.76% / 35.06%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight33.04% / 34.35%Peak / Non PeakSales & BSR Performance
Loading samples... 29%